Chronic Myelomonocytic Leukemia Clinical Trial Pipeline Analysis Demonstrates 22+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
13. August 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Chronic Myelomonocytic Leukemia Clinical Trial Pipeline Analysis Demonstrates 22+ Key Companies at the Horizon Expected to Transform the Treatment...
Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones
07. Mai 2019 16:05 ET
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA...
Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC
22. Oktober 2018 08:45 ET
|
Kura Oncology, Inc.
– Nine patients with HRAS mutant HNSCC experienced tumor size reductions, including six confirmed PRs and two patients with disease stabilization greater than six months – – One additional HNSCC...
Kura Oncology to Present at Leerink Partners Rare Disease & Oncology Roundtable
26. September 2018 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Present at H.C. Wainwright Global Investment Conference
30. August 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Present at 2018 Wedbush PacGrow Healthcare Conference
07. August 2018 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
06. August 2018 16:05 ET
|
Kura Oncology, Inc.
– Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at ESMO 2018 – – Startup activities initiated for upcoming...
Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock
28. Juni 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial
20. Juni 2018 07:30 ET
|
Kura Oncology, Inc.
– John Farnam appointed to newly created position of Chief Operating Officer – – Bridget Martell, M.D., and Blake Tomkinson, Ph.D., join as Vice Presidents of Clinical Development – –...
Kura Oncology to Present at JMP Securities Life Sciences Conference
14. Juni 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 14, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...